Identification and characterization of the molecular lesion causing mucopolysaccharidosis type I in cats

被引:37
|
作者
He, XX
Li, CM
Simonaro, CM
Wan, Q
Haskins, ME
Desnick, RJ
Schuchman, EH
机构
[1] CUNY Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA
[2] CUNY Mt Sinai Sch Med, Inst Gene Therapy & Mol Med, New York, NY 10029 USA
[3] Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA
关键词
lysosomal storage diseases; animal models; mucopolysaccharidoses;
D O I
10.1006/mgme.1999.2860
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mucopolysaccharidosis Type I (MPS I) is the lysosomal storage disease caused by the deficient activity of alpha-L-iduronidase (IDUA). In man, MPS I can occur in severe, mild, or intermediate forms known as the Hurler, Scheie, or Hurler/Scheie syndromes, respectively. RIPS I also has been described in cats, dogs, and mice. This manuscript reports the identification and characterization of the mutation causing RIPS I in cats. To obtain wild-type feline IDUA cDNAs, two PCR-based strategies were used. PCR primers were constructed from a conserved region of the published human and dog sequences and used to amplify a 224-bp IDUA fragment from normal cat genomic DNA. This fragment was then used to screen a feline uterus cDNA library. PCR also was used to directly amplify IDUA fragments from the same cDNA library. Two overlapping feline IDUA cDNAs encoding 466 amino acid residues of the feline IDUA polypeptide (similar to 85% of the mature protein based on comparison to the human, dog, and mouse sequences) were obtained by these strategies. To identify the mutation causing NIPS I in cats, DNA sequencing was carried out on the corresponding IDUA region from several affected animals. A 3-bp deletion was found on both IDUA alleles in each of the MPS I animals, predicting the deletion of a single aspartate residue from the feline IDUA polypeptide. To confirm the authenticity of this mutation, heteroduplex, SSCP, and transient expression studies were carried out. Over 100 animals from the RIPS I colony were screened for the presence of the mutation by heteroduplex and SSCP analyses-in all cases the presence of the 3-bp deletion was 100% concordant with the disease phenotype. For transient expression studies, the two partial, overlapping feline cDNAs were combined and joined in-frame to the 5' end of the canine IDUA cDNA. This wild-type, hybrid cDNA expressed IDUA activity up to sixfold over endogenous levels after transfection into COS-1 cells. A modified full-length IDUA cDNA containing the 3-bp deletion did not express IDUA activity in a transient expression system, providing proof that this lesion was the cause of feline MPS I. (C) 1999 Academic Press.
引用
收藏
页码:106 / 112
页数:7
相关论文
共 50 条
  • [41] Laronidase for treating mucopolysaccharidosis type I
    El Dib, R. P.
    Pastores, G. M.
    GENETICS AND MOLECULAR RESEARCH, 2007, 6 (03): : 667 - 674
  • [42] A few challenges in mucopolysaccharidosis type I
    Bay, Luisa
    Amartino, Hernan
    Antacle, Alejandra
    Arberas, Claudia
    Berretta, Adriana
    Botto, Hugo
    Cazalas, Mariana
    Copiz, Adriana
    De Cunto, Carmen
    Drelichman, Guillermo
    Espada, Graciela
    Eiroa, Hernan
    Fainboim, Alejandro
    Fano, Virginia
    Guelber, Norberto
    Maffey, Alberto
    Parisi, Claudio
    Pereyra, Marcela
    Remondino, Rodrigo
    Schenone, Andrea
    Specola, Norma
    Staciuk, Raquel
    Zuccaro, Graciela
    ARCHIVOS ARGENTINOS DE PEDIATRIA, 2021, 119 (03): : E193 - E201
  • [43] Advances in the treatment of mucopolysaccharidosis type I
    Muenzer, J
    Fisher, A
    NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (19): : 1932 - 1934
  • [44] Clinical, biochemical, and molecular characterization of mucopolysaccharidosis type III in 34 Egyptian patients
    Almenabawy, Nihal
    Ramadan, Manal
    Kamel, Mona
    Mahmoud, Iman G.
    Amer, Fawzia
    Shaheen, Yara
    Elnaggar, Walaa
    Selim, Laila
    AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2023, 191 (09) : 2355 - 2363
  • [45] Mucopolysaccharidosis type I in the Cuban population
    Menéndez-Sainz, C
    Zaldívar-Muñoz, C
    González-Quevedo, A
    REVISTA DE NEUROLOGIA, 2003, 37 (06) : 525 - 528
  • [46] Molecular Analysis of 30 Mucopolysaccharidosis Type I Patients: Evaluation of the Mutational Spectrum in Italian Population and Identification of 13 Novel Mutations
    Venturi, N.
    Rovelli, A.
    Parini, R.
    Menni, F.
    Brambillasca, F.
    Bertagnolio, F.
    Uziel, G.
    Gatti, R.
    Filocamo, M.
    Donati, M. A.
    Biondi, A.
    Goldwurm, S.
    HUMAN MUTATION, 2002, 20 (03) : 231
  • [47] Molecular cloning and characterization of a full-length complementary DNA encoding human acid ceramidase - Identification of the first molecular lesion causing Farber disease
    Koch, J
    Gartner, S
    Li, CM
    Quintern, LE
    Bernardo, K
    Levran, O
    Schnabel, D
    Desnick, RJ
    Schuchman, EH
    Sandhoff, K
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (51) : 33110 - 33115
  • [48] Mucopolysaccharidosis type I:: identification of alpha-L-iduronidase mutations in Tunisian families
    Chkioua, L.
    Khedhiri, S.
    Jaidane, Z.
    Ferchichi, S.
    Habib, S.
    Froissart, R.
    Bonnet, V.
    Chaabouni, M.
    Dandana, A.
    Jrad, T.
    Limem, H.
    Maire, I.
    Abdelhedi, M.
    Laradia, S.
    ARCHIVES DE PEDIATRIE, 2007, 14 (10): : 1183 - 1189
  • [49] Different ARSB variants causing mucopolysaccharidosis type VI in dogs
    Wang, Ping
    Margolis, Carol
    Lin, Gloria
    Raj, Karthik
    Han, Rachel
    Berman, Lisa
    Foureman, Polly
    Sewell, Adrian
    Giger, Urs
    MOLECULAR GENETICS AND METABOLISM, 2017, 120 (1-2) : S137 - S137
  • [50] GLYCOSAMINOGLYCANS AS ANTICOAGULANTS IN MUCOPOLYSACCHARIDOSIS TYPE I (MPS I)
    Tolar, J.
    Orchard, P. J.
    Key, N.
    Blazar, B. R.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (02) : 46 - 46